Skip to content

Main Navigation

Sbio Logo 2025 2
  • Careers
  • Partnerships
  • Investors
  • Contact
  • Search
  • Our Company
    • About Us
    • Founding Story
    • Our Values In Action
    • Who We Are
  • Our Approach
    • Approach Overview
    • The Autoimmune Problem
    • Our Concept
    • Our Science
    • Publications
    • Manufacturing
  • Platform & Pipeline
    • Platform
    • Pipeline
  • Our Focus
  • Clinical Trials
  • News
    • Press Releases
    • In the News

Publications

Harnessing regulatory T cells to establish immune tolerance

Array
•

Chimeric cytokine receptor provides IL-2 signaling for engineered regulatory T cell therapy

Array
•

Opportunities for Treg cell therapy for the treatment of human disease

Array
•

Polyclonal Regulatory T Cell Manufacturing Under cGMP: A Decade of Experience

Array
•

Immunotherapy: Building a bridge to a cure for type 1 diabetes

Array
•

Foxp3: a genetic foundation for regulatory T cell differentiation and function

Array
•

Treg cell-based therapies: challenges and perspectives

Array
•

Next-generation regulatory T cell therapy

Array
•

Therapeutic use of regulatory T cells for graft-versus-host disease

Array
•

Posts navigation

  • 1
  • 2
  • »
Sbio Logo 2025 2 White
  • Our Company
    • Founding Story
    • Our Values In Action
    • People & Culture
    • Who We Are
    • Our Focus
    • Clinical Trials
  • Platform & Pipeline
    • Platform
    • Pipeline
  • Our Approach
    • The Autoimmune Problem
    • Our Concept
    • Our Science
    • Publications
    • Manufacturing
  • Careers
  • Partnerships
  • Investors
  • News
  • Contact

© 2025 Sonoma Biotherapeutics.

LinkedIn Twitter
  • Privacy Policy
  • Terms of Use